The objective of this study is to estimate the prevalence of VKORC1, CYP2C9, and CYP4F2 genetic variants and their contribution to warfarin dose variability in Qataris. One hundred and fifty warfarin-treated Qatari patients on a stable dose and with a therapeutic INR for at least three consecutive clinic visits were recruited. Saliva samples were collected using Oragene DNA self-collection kit, followed by DNA purification and genotyping via TaqMan Real-Time-PCR assay. The population was stratified into derivation and validation cohorts for the dosing model. The minor allele frequency (MAF)
Introduction
Warfarin is the most widely used oral anticoagulant for the treatment and prevention of thromboembolic manifestations associated with atrial fibrillation, valve replacement, orthopedic surgery, and venous thrombosis [1] . It accounts for about 1% of annually prescribed medications in the Western world [2] . Despite the introduction of direct oral anticoagulants over the last decade, warfarin is still the mainstay oral anticoagulant [3] . Warfarin is a vitamin K antagonist that inhibits the vitamin K cycle by binding to the vitamin K epoxide reductase (VKOR) and preventing the formation of sulfhydryles, which are essential for vitamin K cycle activity [4, 5] . This leads to the inhibition of the activation of several vitamin K-dependent clotting factors. Warfarin is administered as a racemic mixture of two optically active enantiomers, the R and the S enantiomers, in almost equal proportions. The S isomer is mainly metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme and is 3-5 times more potent than the R isomer, but has faster clearance [6] . One of the major disadvantages of warfarin is its narrow therapeutic index, which can lead to serious bleeding or thrombotic adverse events that can even cause death [7] . Another challenge associated with warfarin treatment is the inter-and intra-patient variability of the dose required to achieve optimal anticoagulation. Warfarin maintenance dose requirements can vary from 0.5 to 20 mg per day [8] . Several factors can contribute to this inter-patient variability including age, body surface area, ethnicity, and genotype [9, 10] . On the other hand, changes in vitamin K intake; febrile or diarrheal disease; alcohol intake; diet; and smoking are among factors contributing to intra-patient dose variability. Genome wide association studies have shown that genetic variations in the VKORC1 and CYP2C9 genes are associated with warfarin dose variability [11] . Variants in the CYP4F2, a gene coding for the vitamin K metabolizing enzyme, were also shown to provide minor contribution to warfarin dose variability [11] .
In Qatar, warfarin is still the mainstay oral anticoagulant. Compared to direct oral anticoagulants, warfarin use comprised 77% of all oral anticoagulants in 2015 [12] . Despite the importance of genetic variations in predicting initial warfarin doses, no prior warfarin pharmacogenetics studies have been carried out on the Qatari population [13] . Therefore, we aimed in this study to fill this gap. Our main objectives were to estimate the frequencies of VKORC1 (−1639G>A), CYP4F2*3 and CYP2C9*2 and *3 variants in Qataris; determine the variability in warfarin dose explained by each genetic variant; and develop and validate a dosing model/algorithm consisting of genetic and nongenetic predictors.
Methods

Research design and ethics
This study is a cross sectional observational study involving a cohort of Qatari patients taking varying doses of warfarin for various indications. Ethical approvals were obtained from the Institutional Review Board (IRB) of Hamad Medical Corporation (HMC), and from Qatar University (QU) IRB.
Study setting and timeline
Patient recruitment was conducted at three different sites, all of which are part of HMC, the biggest medical institution in Qatar. These included the anticoagulation clinics at Al-Wakra Hospital, the Heart Hospital, and Hamad General Hospital. Recruitment started in September 2016, and was completed in March, 2017. DNA samples were processed and analyzed at the laboratories of Qatar University, between November, 2016 and June, 2017.
Study population and sampling
This study included warfarin-treated patients of the Qatari nationality only (identified as being Qatari passport holders). Because of the limited number of Qatari patients on warfarin (about 1000 patients) [12] , a sample of convenience was used.
Patients were considered eligible if they had been on warfarin for at least 6 weeks, had been on a stable warfarin dose for at least three consecutive clinic visits with their INR in therapeutic range, agreed to participate in the study and signed a written informed consent form. A stable warfarin dose was defined as a dose that did not vary by more than 10% between clinic visits [14] . Patients were excluded if they had liver cirrhosis, had advanced malignancies, were hospitalized within the previous four weeks or had a diarrheal or febrile disease within the previous 2 weeks.
Data collection and outcome measures
The primary outcome of our study was stable weekly warfarin dose defined as: mean weekly dose at which INR readings were in the therapeutic range for three consecutive clinic visits, with at least 5 days between readings and no more than 10% variation in the dose between clinic visits.
After signing a written informed consent, patients were asked to provide saliva sample (or blood sample if unable to provide saliva due to mouth dryness). Saliva samples were collected using the Oragene•DNA® (OG-500) selfcollection kit (DNA genotek TM , Canada), following the manufacturer's instruction. Blood samples were collected by a trained nurse/phlebotomist using BD Vacutainer® K3 EDTA 12.15 mg (15% Sol, 0.081 mL) glass collection tubes (Reference number 366450). Clinical and demographic data were obtained mostly from patients' medical records.
DNA extraction, quantification, and genotyping
Genomic DNA was extracted from fresh frozen whole blood samples using the PureLink® Genomic DNA mini kits, Invitrogen TM , following the manufacturer protocol [15] . Extraction of DNA from saliva samples was performed using the prepIT®•L2P manual protocol for the purification of DNA from 0.5 ml sample [16] . The Nanodrop 2000c Spectrophotometer (Thermo Fisher Scientific TM ) was used to quantify and assess the quality of extracted DNA. For SNP detection and genotyping, we used the real-time polymerase chain reaction (RT-PCR) 7500 Fast System with the TaqMan drug metabolizing enzyme genotyping assay, Applied Biosystems TM , Life Technologies. All probes were purchased at ThermoFisher Scientific, their context sequences are listed in supplementary Table S1 . The genotyping of all the variants was repeated by an independent researcher blinded to the samples' warfarin dosing.
Statistical analysis
Descriptive statistics and normality tests were used to analyze baseline demographics. Chi-square-Goodness of Fit was used to make sure that all allele frequencies fit the Hardy-Weinberg equilibrium (HWE). A P value of more than 0.05 indicated that allele frequencies fits HWE. The independent sample t-test, and ANOVA tests were used to compare continuous variables that are normally distributed. Nonparametric tests (Mann-Whitney U or Kruskal-Wallis) were used to compare weekly warfarin dose since it was not normally distributed. To adjust for multiple comparisons, Bonferroni correction was performed by dividing the P value (0.05) by the number of SNPs tested (4 SNPs). Any P value of 0.01 or less was considered significant.
Stratification and randomization
The population was stratified into derivation and validation cohorts for the dosing model. To assure the homogeneity of both the derivation and validation cohorts, samples were first stratified by dose using the interquartile range. Samples in the first quartile were considered as low dose, samples in the fourth quartile were considered high dose, and anything between the second and third were considered as moderate. Samples were then randomized to have 70% in the derivation cohort and 30% in validation cohort, using computer randomization.
Simple linear regression (SLR) modeling was used to estimate the effect of each genetic and nongenetic factor studied on warfarin dose variability. Furthermore, we relied on the results of SLR to decide which factors to include in model development, any factor with a p value of 0.2 or below was included.
Multiple linear regression modeling with both backward elimination selection and stepwise selection was used to develop the dosing model. We tried all three models: recessive; dominant; and additive, and chose the one with the highest R-square value. To validate the dosing model we calculated the Spearman's correlation coefficient and mean absolute error. IBM Statistical Package for Social Sciences (IBM SPSS 24 software IBM, New York, USA) was used to perform all the analyses.
Sample size calculation
Since regression usually requires higher sample sizes than other statistical tests, we did our sample size calculation only for the regression objective. For an anticipated effect size (ƒ 2 ) of 0.2, statistical power of 0.8, 15 predictors, and an alpha level of 0.05, it was estimated that a sample size of 107 would be required. To account for patient withdrawal and model validation, a total of 150 patients was considered adequate. Sample size calculations were performed using Soper, D.S. (2017), a multiple regression sample size calculator (http://www.danielsoper.com/statcalc).
Results
Patient recruitment and study population characteristics
A total of 172 patients were approached, and 150 patients were recruited in the study (82% response rate). Only 149 patients were included in the analysis due to poor quality of one of the samples where no DNA was detected. Table 1 shows the demographic characteristics of our studied population. Mean warfarin weekly dose in our entire cohort was 34.5 ± 15.7 and ranged from 9.5 to 91 mg/week (almost tenfold inter-patient dose variability).
Prevalence of VKORC1, CYP2C9, and CYP4F2 variants
To estimate the prevalence of our studied genetic variants we calculated their minor allele frequency (MAF), which are all shown in Table 2 along with MAF's in other Middle East and North Africa (MENA) populations. The genotype frequencies are shown in Table 1 , for both the validation and the derivation cohort. No deviations from HWE were observed for any of the genotype frequencies.
Association of genetic and nongenetic factors with warfarin dose
In the overall cohort (n = 149), Mann-Whitney U test showed that CYP2C9 decreased function alleles (CYP2C9 *2 & *3) (rs1799853 and rs1057910, respectively) required lower median (IQR) weekly doses compared to those with the *1/*1 genotype [24.5(14.5) mg/week vs. 35(21.8) mg/ week, p < 0.001] (Fig. 1 ). Kruskal-Wallis showed that median warfarin dose requirements were significantly different among the three alleles [14 mg/week for carriers of two copies decreased CYP2C9 variants, 24.5(12.5) mg/ week for carriers of one copy variant, and 35(21.8) mg/ week for *1/*1 genotype, p < 0.0001]. Post-hoc Pairwise comparisons showed only a significant difference between carriers of 1 copy variant and *1/*1 (p < 0.0001). While carriers of two copies CYP2C9 variants had much lower median warfarin dose compared to the other genotypes, they were not significantly different likely due to the very small sample size of homozygote CYP2C9 allele carriers (n = 3). Table 3 shows dose requirements by each of the CYP2C9 genotype groups.
Similarly, there were significant differences in median dose requirements between the different genotype groups of VKORC1-1639G>A (rs9934438) [GG 43.7(15) mg/week, AG 31.5(18.7) mg/week, AA 21(7.5) mg/week, p < 0.0001] (Fig. 2) . Post-hoc pairwise comparisons showed significant difference between all three pairs (p < 0.0001). No significant difference in median (IQR) weekly dose was found between carriers and noncarriers of CYP4F2*3 (rs2108622) [32.2 (75.2) mg/week, vs. 28 (21) mg/week, p = 0.71] ( Supplementary Fig. S1 ).
In the derivation cohort, simple linear regression showed that age, height, hypertension (HTN), heart failure (HF), smoking, statin, CYP2C9, and VKORC1 are all significant predictors of warfarin dose with p value less than 0.05 ( Supplementary Table S2 ). The CYP2C9 and VKORC1 had the lowest p value (<0.001) and the highest adjusted-R 2 . They both explained 10.6% and 14.8% of the dose variability, respectively. It should be noted that we used the genetic model that yielded the highest adjusted-R 2 . For CYP2C9 variants, data were based on dominant model, while VKORC1 data were based on additive model.
Derivation and validation of the dosing model/ algorithm
Since the derivation cohort's weekly warfarin dose was skewed, log transformation was performed prior to the regression analysis. Multiple linear regression, in both backward elimination and stepwise selection, showed that having HTN, HF, being a smoker, and carrying at least one of the CYP2C9 and VKORC1 minor alleles were the significant predictors of warfarin dose, and together they explained 39.2% of the dose variability in the derivation cohort (Table 4 ). The bolded values represents results from this stuy (1), nonsmoker (0) d carrying 2 copies of the "A" variant (2), 1 copies of the "A" variant (1), non-carriers (0) e carrying at least 1 of the *2 or *3 minor alleles (1), noncarriers (0). No significant differences were found between the validation and the derivation cohort in terms of all demographic, clinical, and genetic characteristics except for: gender, indication for warfarin, having diabetes or HTN, and genotype frequencies of CYP4F2*3 (Table 1) . To validate the regression model produced from the derivation cohort, we calculated the predicted warfarin doses using the dosing model and then compared it to the observed doses in the validation cohort. We found good correlation between the predictedph and observed doses (Spearman's rho correlation coefficient = 0.711, p < 0.001) ( Supplementary  Fig. S2 ). However, mean percentage absolute error was high (53.8 ± 23.2%). Interestingly, our model had much better accuracy predicting the dose for patients with a dose of less than 35 mg/week compared to those with higher weekly dose. This was evident when we compared the mean percentage absolute error for patients with a weekly dose of less than 35 mg compared to those with higher weekly dose (5.5 ± 3.8% vs 59.6 ± 16.4%, p < 0.001).
Discussion
Qatar is a peninsula in the Persian/Arabian Gulf. It resides at the eastern edge of the Arabian Peninsula, which makes it at the center of migration patterns that took part in the region over the era of human history [17] . Various migrations and historical events have created a genomic admixed Qatari population consisting mainly of Arabic (mainly Bedouins), Persian (Iran, Pakistan and Afghanistan), and African (Sub-Saharan Africa) ancestry [17] . A high rate of consanguinity still exists among Qataris (35% in 2010), with first cousins' marriages being widely accepted and predominant [18] . Such high levels of consanguinity may have had a profound influence on the genetic make-up of this population [19] . No previous studies have explored the effect of genetic variants on warfarin dose variability in Qataris.
Our study indicates that the prevalence of CYP2C9*2 is 12%, which replicates what was previously found by Sivadas et al. from the whole exome datasets in Qataris [20] . The prevalence of CYP2C9*3 and CYP4F2*3 alleles in our study was also similar to that previously reported (4% and 43% vs. 2% and 38%, respectively) [20] . This study is the first to report the MAF of VKORC1-1639G>A in Qataris and it was 47%, resembling Saudi (42.4%), Egyptian (46.2%), Turkish (49%), and Kuwaiti populations (40%) [14, [21] [22] [23] . The CYP2C9*2 MAF was comparable to Saudi, Israeli, Jordanian, Egyptian, Kuwaiti, and Turkish populations, which were all between 11 and 14% [14, [21] [22] [23] [24] [25] [26] . Furthermore, CYP2C9*3 frequency was the same as Kuwaiti and close to Saudi (2%), but lower than in other populations of MENA, which were between 6 and 11%, except for Sudanese where this variant was not detected [21, 23, 27] . Even though many Qataris descend from at least one Iranian parent, allele frequencies differed between our population and Iranians. The CYP2C9*2 and Kruskal-Wallis test was used to compare the median warfarin dose between the three genotype groups. Post-hoc pairwise comparisons showed significant difference between all three pairs (p < 0.0001) *3 frequencies are twice as high in Iranian compared to Qatari [28] . Looking outside the MENA region, the VKORC1 and CYP2C9*2 MAF's were closer to Europeans (36.1% and 12.5%) than to African Americans (10.6% and 1.9%) or Asians (87% and 0%) [29, 30] . The CYP2C9*3 frequency on the other hand, resembled Asians (3%) as compared to Europeans (6.3%) or African Americans (1.9%) [29] .
The VKOR is the target enzyme for warfarin and variants in its encoding gene (VKORC1) were shown to be the biggest predictors of warfarin dose [31] . Similar to other studies, we showed that carriers of the G-1639A variant require significantly lower doses compared to noncarriers. Furthermore, median weekly dose was less with each added copy of the A variant. In 2008, Limdi et. al. reported the VKORC1-1639 to be a predictor of warfarin dose in Asians, Blacks, and Whites. However, the contribution of this variant to dose variability varied from one race to another, reflecting its varying frequencies in different race groups. The VKORC1-1639 was the biggest predictor of warfarin dose in our population explaining 14.8% of the variability.
We found a significant association between dose requirements and CYP2C9*2 & *3. Patients carrying any decreased function CYP2C9 allele (*1*2, *1*3, *2*3, or *3*3) had significantly lower doses than those with the *1/*1 genotype. These findings greatly resemble those found in other countries from the MENA region and worldwide [14, 21, 22, 25, 28] . Variants of the CYP2C9 were good predictors of warfarin dose in our population explaining 10.6% of the variability.
Although CYP4F2*3 was highly prevalent in Qataris, it did not show any significant association with warfarin dose requirements. Our findings are consistent with Egyptians, where no significant difference was found between carriers and noncarriers of CYP4F2*3, p = 0.31 [14] .
Our final dosing model included: HF, smoking, VKORC1 and CYP2C9 and explained almost 40% of dose variability. Significant correlation was found between predicted and actual mean weekly doses. The final dosing model showed good prediction for the validation cohort, especially in these patients requiring lower warfarin dosing (<35 mg/week). This interesting result could be attributed to not including other less common missense mutations that are associated with warfarin resistance including: Asp36Tyr, Tyr139Cys, Val45Ala, Val25leu, and Arg58Gly [32] . The effect of these variants has not been widely studied except for the VKORC1 Asp36Tyr. Shahin et al, in their study on the prevalence of this variant, have reported its existence mainly in all Northern African and Middle Eastern countries and its absence in West Africans or African Americans and Peruvians [33] . This remains to be confirmed in future studies to test if these mutations would contribute further to our prediction model especially for those patients requiring larger warfarin dose.
Study limitations
This study was limited by the small sample size. Power calculations were limited to the derivation model cohort only. In addition, splitting the sample size into derivation and replication cohorts, may have further reduced the sample size leading to a problem of over-fitting in the dosing algorithm. The genetic sub-structure of the Qatari population was not accounted for in the present study, which may have had a major influence on our study results. Dietary vitamin K, and adherence to warfarin treatment, were not accounted for in our analysis. We used the inheritance model that yielded the highest R 2 which may not reflect the true mode of inheritance. Our focus in this study was on VKORC1-1639G>A, CYP2C9*2 & *3, and CYP4F2*3 and their association with warfarin dose. However, other less common variants may have had an impact on warfarin dose requirement in Qatari. Not including these variants in our analysis may have affected the study results.
Conclusions
This study showed significant association between warfarin dose requirements and the VKORC1 (−1639G>A) and CYP2C9*2 & *3 variants in Qatari population. Dose reduction should likely be considered in patients carrying these variants alleles. There was no significant association found between warfarin dose and CYP4F2*3 in Qatari, despite its high frequency. A dosing algorithm consisting of smoking, HTN, HF, VKORC1 (−1639G>A) and CYP2C9*2 & *3 could predict warfarin dose for the Qatari population to a good extent.
Compliance with ethical standards
